Pay in 4 interest-free payments of $5.17 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
discontinued CJC-1295 (DAC) Not FDA-approved Feature Phase III Trial Data Tesamorelin Yes (n=816 pooled) Sermorelin No adult Phase III VAT datasets CJC-1295 (DAC) No Feature Visceral Fat Reduction Tesamorelin 15-20% at 26 weeks Sermorelin Not formally studied in RCTs CJC-1295 (DAC) Not formally studied in RCTs Feature Liver Fat Reduction Tesamorelin 32% at 12 months (NAFLD trial) Sermorelin Not studied CJC-1295 (DAC) Not studied Feature Typical Research Dose Tesamorelin 2 mg daily Sermorelin 200-300 mcg nightly CJC-1295 (DAC) 1-2 mg weekly Feature Unique Advantage Tesamorelin Only FDA-approved GHRH with deepest trial evidence Sermorelin Longest historical track record CJC-1295 (DAC) Weekly dosing convenience Tesamorelin is the only GHRH peptide with active FDA approval and validated Phase III visceral-fat data
The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review
Whether it be with independent reviews on Reddit, or with signing some pretty big names in the bodybuilding world
This calculation incorporates cholesterol levels, blood pressure, smoking status, and other factors to guide treatment decisions
PubMed ReviewGrowth-hormone peptide evidence2001 The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation Preclinical context that should not be overstated as consumer clinical evidence
